Compare Apple Inc (AAPL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs BioNano Genomics Inc — how do they compare? Apple Inc trades at $301.55 (market cap $4.45T), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Apple Inc is far larger — about 325768.7× BioNano Genomics Inc's market cap, and Apple Inc pays a 0.35% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AAPL | BNGO | |
|---|---|---|
Market Cap | $4.45T | $13.66M |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $4.92 |
52-Week Low | $224.90 | $1.06 |
Enterprise Value | $4.47T | $16.26M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.14, down 2.31% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 26.91%. However, valuation ratios like P/E of 34.97 and P/B of 41.39 appear elevated. Recent news highlights AI potential through its device ecosystem but also store closures and union disputes.
The outlook is mixed: solid fundamentals and analyst buy consensus support upside to the $337.63 price target, but high valuations and technical bearishness near-term pose risks. Key opportunities include AI integration and cash flow strength; risks involve competitive pressures, regulatory scrutiny, and execution on growth initiatives.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
